gression/nonprogressor" (LTNP) in studies of adults, resulting in 1%-25% of HIV-1-infected persons being classified as LTNPs after 8-10 years of infection [7] [8] [9] . These definitions are based mostly on quantitative immunological criteria in patients who have not received treatment, and in some studies, the definition has involved clinical criteria (i.e., the absence of AIDS-defining symptoms or even the absence of any symptoms linked to HIV-1 infection). Some studies also distinguish a subgroup of LTNPs who have persistently low HIV-1 loads [10] . The particularly slow progression of HIV-1 infection in these patients may be associated, at least in part, with a genetic profile in the host that limits viral replication and/or affects the quality of the specific anti-HIV-1 immune response (reviewed in [11, 12] . In the vast majority of cases, the replicative capacities of the virus do not appear to be modified [13, 14] . However, it remains unclear whether LTNPs are a particular subgroup of patients who experience no adverse effects of HIV-1 infection or are simply persons at the tail end of the survival curve.
Definitions applied to adults need to be adapted to the specificities of pediatric care before they can be used for children. CD4
+ cell counts, expressed as absolute cell counts, are higher in infants than in older children and, in fact, decrease over the first few years of life [15] . In addition, children may develop opportunistic infections at higher CD4 + cell counts, compared with adults, as confirmed by a recent meta-analysis. CD4
+ cell percentages are a better marker than absolute CD4 + cell counts, which vary more with age in children [16] .
Our objective was to estimate the proportion of LTNPs in the French Pediatric HIV-1 Cohort (EPF), one of the largest and oldest incident cohorts of children who were infected with HIV-1 at birth. We used a definition of LTNP derived from definitions generally used for adults: continual maintenance of a high CD4 + cell percentage and an absence of HIV-1-related symptoms, without receipt of antiretroviral treatment, at the age of 10 years. We assessed various CD4 + cell percentage thresholds and various definitions of HIV-1-related symptoms. We then studied perinatal characteristics associated with LTNP.
PATIENTS AND METHODS
The EPF. The ongoing EPF study has prospectively collected data concerning HIV-1-infected pregnant women and their children in 90 health care centers throughout France since 1986. Informed consent was obtained from all mothers during pregnancy or at delivery. The cohort study was approved, in accordance with French law, by the Cochin Hospital Institutional Review Board and the French computer database watchdog commission (Commission Nationale de l'Informatique et des Libertés).
As previously reported [17] , HIV-1-uninfected children were observed in accordance with recommended standards of care, including clinical and biological examination at birth; at ages 1, 3, and 6 months; and then every 6 months until they were 24 months of age. HIV-1-infected children were observed until adulthood. No specific recommendations for HIV-1 treatment or obstetrical care were made for women and children enrolled in the cohort, although investigators were encouraged to follow French national guidelines, as regularly published and updated [18] .
Study population. Among the 12,325 children born to HIV-1-infected mothers included in the EPF cohort up to 15 December 2006, a total of 568 were infected with HIV-1. All 348 HIV-1-infected children born before 1 January 1994 were included in this analysis: these persons were old enough to have undergone at least 12 years of follow-up and did not receive perinatal prophylaxis for mother-to-child transmission of HIV-1 (such prophylaxis was not yet available at that time). HIV-1 infection in children was defined on the basis of 2 positive HIV-1 PCR results or 2 positive culture results before the age of 18 months, positive results of a serologic test after the age of 18 months, or AIDS-related death before the age of 18 months in the absence of viral isolation (especially for children born before PCR testing was available). Follow-up was censored at the French legal age for adulthood (i.e., 18 years) for all children.
Definitions of LTNP. We initially defined LTNPs as HIV-1-infected children who had been observed for at least 10 years, who had never received antiretroviral treatment (other than zidovudine monotherapy), who had never developed symptoms of Centers for Disease Control and Prevention (CDC) clinical category C or B, and for whom the CD4 + cell percentage was !25% no more than once throughout the follow-up period before they reached 10 years of age. This threshold for the CD4 + cell percentage corresponds with the highest of the 3 immunological categories of the 1994 CDC classification for HIV-1-infected children, defined as "no evidence of immunosuppression" [15] . Zidovudine monotherapy alone was allowed, because it has no long-term immunological and clinical efficacy, either in adults or children [19, 20] . In accordance with the inclusion period criteria, no child had received perinatal antiretroviral prophylaxis. We then considered less restrictive clinical and immunological definitions (i.e., use of only AIDSdefining events [CDC category C] as a marker of clinical progression and use of a CD4 + cell percentage threshold of 15% rather than 25%).
We also examined the effect of considering only nontreated children (with zidovudine monotherapy again excluded) or of allowing children who had received dual-nucleoside analogue therapy. In the latter instance, only children treated with HAART were excluded from the definition of LTNP, with HAART defined as the combination of у3 antiretroviral drugs.
The studied maternal characteristics were age at the time of delivery; geographic origin, as classified in 3 categories (sub- Saharan Africa, Caribbean, and other); last CD4 + cell count during pregnancy; and CDC class. Neonatal characteristics considered were sex; prematurity (i.e., age of !33 and 33-36 gestational weeks); in utero transmission of HIV-1 (positive HIV-1 PCR or culture result in the first 7 days of life); height, weight, and head circumference at birth; and CD4 + and CD8 + cell percentages in the first 3 months of life. HIV-1 RNA loads during the first weeks of life were not available for most of these children, who were born before 1994. Statistical analysis. The cumulative incidence of LTNP was estimated and plotted using the Kaplan-Meier method. Failure was defined as the first event of the following to occur: death, CDC clinical class C or B, a second CD4 + cell percentage of !25% or !15%, or first prescription of zidovudine monotherapy, dual-nucleoside reverse-transcriptase inhibitor therapy, or HAART. Children who did not have progression, as determined by the aforementioned criteria, at the last available examination before 1 July 2006 were considered to be LTNPs. Ninety-five percent CIs of Kaplan-Meier survival estimates were estimated using the method of Kalbfleisch and Prentice [21] . Survival curves were compared on the basis of perinatal characteristics using log rank tests. The mean slope of the CD4 + cell percentage between 2 and 10 years for LTNPs was estimated using a random effects model. Statistical analyses were performed using SAS software (SAS Institute). The evolution of the CD4 + cell percentage between 2 and 10 years for LTNPs was plotted using the nonparametric smoothing technique with R software (Development Core Team).
RESULTS

Probability of LTNP.
Among the 348 HIV-1-infected children born before 1 January 1994, the median effective duration of follow-up (i.e., when the last questionnaire was received) was 12.9 years (interquartile range, 5-15.4 years). Forty-eight children were lost to follow-up, 11 of whom were lost to followup during the 2 first years of life. At 8, 10, 12, 14, and 16 years, 229, 217, 200, 139 , and 57 children, respectively, were still alive and undergoing regular follow-up. Overall, 299 children (86%) developed AIDS-defining symptoms (CDC class C) or less severe symptoms (CDC class B), presented with a CD4 + cell percentage !25% on at least 2 occasions, or died before receiving treatment, most of them before 1996 ( [all n p 186 events]). No children received dual-nucleoside analogue therapy before experiencing clinical or immunological progression. However, since 1996, 17 children (5%) have received HAART before experiencing any clinical or immunological progression; therefore, they were not considered to be LTNPs. According to this definition of LTNP (i.e., CD4 + cell percentage of у25%, no CDC category B or C events, and no receipt of treatment other than zidovudine monotherapy), the Kaplan-Meier estimate of long-term survival probabilities at 10 years of age was 2.4% (95% CI, 1.1%-4.6%), with 7 children meeting the criteria for LTNP. The Kaplan-Meier estimates decreased slightly with age, to 1.8% ( ) at 12 years of age and 1.4% ( ) at n p 5 n p 4 14 years of age. The last LTNP follow-up visit was censored at 193 months (figure 1).
Factors associated with progression of HIV-1 infection. Maternal clinical and immunological status during pregnancy was associated with the child's progression, in accordance with the aforementioned definition (table 1). The time to progression was shorter if the mother's infection reached CDC class C before delivery ( ) and if the mother's last absolute P p .002 CD4 + cell count before delivery was low ( ). Progression P p .02 was also associated with prematurity ( ) and the child's P p .002 immunological status during the first 3 months of life. Progression of HIV-1 infection occurred less rapidly in children who initially presented with a high CD4 + cell percentage (P ! ), low CD8 + cell percentage ( ), and a high ratio .001 P p .003 of CD4
+ cell percentage to CD8 + cell percentage ( ). P ! .001 Children born to African mothers had more rapid progression than did other children ( ). Neither sex nor growth P p .02 markers at birth (i.e., height, weight, and head circumference) were associated with progression of HIV-1 infection. However, factors associated with progression only concerned progression during the early years of life: for children who were still nonprogressors at the age of 2 years, no factors were significantly ). P p .34 associated with subsequent progression, except the maternal clinical CDC stage at delivery.
Growth markers, HIV-1 load, and CD4 + cell data in LTNPs. Among the 7 children who fulfilled the criteria for LTNP at 10 years of age, the median CD4 + cell percentage and count were 35% and 812 cells/mm 3 , respectively. The slope of the CD4 + cell percentage through the time between 2 and 10 years of age was not significantly different from 0 (+0.2% per year; P p ) in a random effects model (figure 2). Height, weight, and .34 body mass index (calculated as weight in kilograms divided by the square of height in meters) were similar to those for the French general population (median body mass index z score at 10 years of age, +0.6 [range, Ϫ0.5 to +1.8] for boys and +0.9 [range, Ϫ0.1 to +2.7] for girls). The mother was still alive for 5 of these 7 children, and the vital status of the mother was unknown for 1 child. The median HIV-1 RNA level at 10 years of age was 2190 copies/mL, with the highest being 23,400 copies/mL (table 2). For 2 children (i.e., 0.6% of the initial eligible population), the HIV-1 load was !1000 copies/mL (125 and 700 copies/mL), and for 1 child, it was 1400 copies/mL. These 3 children remained untreated at the most recent follow-up visit, because they had low viral loads (!50, 90, and 388 copies/ mL at 13.5, 17, and 16 years of age, respectively). Of the 4 other children who presented with higher viral loads at 10 years of age, 2 remained untreated at the most recent follow-up visit, when they were 115 years of age, and 2 were subsequently given HAART.
Differences based on various LTNP definitions. The application of a less restrictive clinical definition of LTNP (i.e., the same threshold immunological criteria but without consideration of the occurrence of CDC category B symptoms as a progression-defining event) resulted in classification of only 1 additional child as a LTNP at 10 years of age (table 2) . In contrast, less restrictive immunological and clinical criteria (i.e., a CD4
+ cell percentage threshold of 15% instead of 25% and only CDC class C symptoms) resulted in the classification of 11 additional children as LTNPs at 10 years of age (table 2) . However, all children but 1 subsequently received treatment. If we used a CD4 + cell percentage threshold of 15% instead of 25% and only CDC class C symptoms, the probabilities of remaining in the LTNP group were similarly low at 8 and 10 years of age, with or without CDC class B symptoms used as a clinical progression event and excluding or including monotherapy in the treatment definition (table 3) . However, when a threshold of 15% was used, Kaplan-Meier estimates varied much more on the basis of age and treatment definitions.
DISCUSSION
According to the definitions we used in this study, which is based on an incident cohort, 2%-16% of children who were infected with HIV-1 at birth and who have been observed since then have presented with slow clinical and immunological progression 110 years after infection. We aimed to estimate this percentage, using a definition based on definitions used for adults that involved the stability of high CD4 + cell percentages, an absence of symptoms, and an absence of antiretroviral treatment, after 8-10 years of follow-up. As a criterion of immunological stability, we used a CD4 + cell percentage that was persistently у25%, allowing the existence of only 1 measure less than this threshold during the course of infection. The absolute CD4
+ cell count in children, unlike that in adults, is not a satisfactory marker, because it decreases during the first few years of life [15, 16] . If the CDC classification of 3 immunological categories (absence of immunosuppression, moderate immunosuppression, and severe immunosuppression) based on absolute CD4 + cell counts, defined in adults as thresholds of 500 and 200 cells/mm 3 [22] , were applied to children, different values would have to be used for different age groups. These thresholds, however, grossly correspond with age-independent CD4 + cell percentages of 25% and 15%. The 15% threshold was used to identify LTNPs in a study of children [14] , but the results obtained here suggested that a threshold of 25% was more relevant for defining the group of children with slow progression. Twice as many of the children who were still alive at the age of 10 years were classified as LTNPs with the threshold of 15% than with the threshold of 25%, but almost all of these additional patients were symptomatic and were rapidly administered HAART. Conversely, most of the children selected with the 25% threshold remained untreated, in accordance with current recommendations, with various durations of follow-up over 10 years.
The principal definition of LTNP did not exclude patients who had received zidovudine monotherapy in the past. This choice, linked to the negative results obtained in a trial of monotherapy in children [20] , was supported by Kaplan-Meier estimates, which were largely unaffected by the inclusion or exclusion of patients who received zidovudine monotherapy, using a minimum CD4 + cell percentage threshold of 25%. By contrast, when the definition of LTNPs included children who had and had not received prior treatment with dual-nucleoside analogue therapy, it led to very different Kaplan-Meier estimates; this provided evidence of the relative efficacy and/or more restricted use of these dual-drug therapies, compared with zidovudine monotherapy, before the generalization of HAART in 1996.
Our most restrictive definition considered all CDC category B and C symptoms to be events that demonstrated clinical progression. Certain CDC category B symptoms (particularly nephropathy and leiomyosarcoma) were associated with high morbidity rates [9, 23, 24] . With the 25% CD4 + cell percentage threshold, the inclusion or exclusion of CDC group B symptoms in the clinical definition made little difference with regard to the number of children identified as LTNPs at the age of 10 years. Conversely, one-half of the additional children identified as LTNPs with use of the 15% CD4 + cell percentage threshold presented with CDC group B symptoms, confirming that this threshold is not as satisfactory for defining the group of children with slow disease progression.
Even with use of the stricter definition, the proportion of children identified as LTNPs using the Kaplan-Meier method continued to decrease after 10 years. Plasma viral replication rates in the children identified as LTNPs varied, as is the case in adults: only one-third of children maintained low or undetectable levels of viral replication beyond the age of 15 years. This observation is consistent with findings in adults, for whom nonprogression associated with spontaneously low or undetectable levels of viral replication is much rarer than clinical and immunological nonprogression. In a recent study, !1% of patients in a cohort of almost 3000 adults had spontaneously low viral loads before receiving treatment [25] . The proportion of children in this cohort with a spontaneously low viral load at the age of у10 years was similar.
The factors associated with immunological and clinical progression are those that are known to be associated with the rapidly progressing form of infection (i.e., the mother's clinical status in utero, infection of the child, prematurity, and initial CD4 + and CD8 + cell counts) [17, 26] . However, with the exception of the stage of maternal infection at the time of the delivery, these factors seem to have little effect on long-term progression. The absence of measures of initial immunological status for some of the infants and the absence of measurements of the initial viral load (which were not routinely available at that time) for most children are limitations of this study and limited our ability to conduct multivariate analyses. The association of LTNP with geographic origin was unexpected, because no such link had been identified in previous analyses of this cohort. Rather than reflecting a high risk of progression of morbidities, this may reflect the physiologically lower CD4 + cell percentage in subjects of African origin, particularly because this association is not observed if the 15% CD4 + cell percentage threshold is used [27] .
According to one study of a cohort of HIV-1-infected children, an absence of activated CD8 + cells (phenotype CD8 + Dr + ) shortly after birth is predictive of LTNP [13] . We did not investigate this immunological factor in our cohort; however, we found that a high CD8 + cell count, expressed as a percentage of lymphocytes, was found to be significantly associated with more rapid clinical and immunological progression. In adults, several immunological factors are associated with LTNP. A strong cellular and/or specific humoral immune response to HIV-1 is often associated with nonprogression [28, 29] . The loss or absence of strong immunity is, nonetheless, compatible with LTNP status [30, 31] . The HIV-1 load shortly after infection is also an independent predictor of LTNP [32] [33] [34] . Several genetic markers of nonprogression have been clearly identified, including polymorphism of the genes of certain chemokine coreceptors (including CCR5 and CX3CR1), the chemokines themselves (including SDF-1), and some HLA haplotypes [5, 6] . Far fewer studies have involved children. However, the same hypotheses have been proposed with regard to viral load, the quality of the immune response, and genetics. An earlier study of our cohort [35] , the results of which were subsequently confirmed by other studies [36] , revealed that rates of morbidity at 8 years of age were lower among children with a heterozygous d mutation in the CCR5 gene than among other children. As in adults, other genes undoubtedly contribute to control of the infection in children [37] . Finally-and more controversiallyobservations of infections with defective viruses have also been associated with LTNP [38] .
The various current consensus texts on the treatment of HIV-1-infected children strongly recommend administration of systematic antiretroviral treatment for all neonates infected with HIV-1, starting immediately after diagnosis of infection [39] . The demonstrated efficacy of this treatment for reducing the risk of encephalopathy and early opportunistic infections justifies this approach [40, 41] . Nonetheless, the risk/benefit ratio for this early treatment of children with slowly or very slowly progressing disease remains to be evaluated. It would be extremely valuable if we could establish a composite collection of immunological, virological, and genetic markers (yet to be defined) that could help predict potential long-term progression and, therefore, contribute to the selection of more targeted treatment.
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